Compare Manchester United PLC (MANU) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs ResMed Inc. — how do they compare? Manchester United PLC trades at $20.63 (market cap $3.51B), while ResMed Inc. trades at $230.78 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 9.1× Manchester United PLC's market cap, and Manchester United PLC pays the higher dividend (1.26%). Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and ResMed Inc. for 51 Days on average.
| MANU | RMD | |
|---|---|---|
Market Cap | $3.51B | $31.89B |
Volume | 412,769 | 618,314 |
Sector | Media | Health |
52-Week High | $24.19 | $277.88 |
52-Week Low | $15.20 | $182.82 |
Typical Hold Time | 109 Days | 51 Days |
Enterprise Value | $4.33B | $31.24B |
Dividend Yield | 1.26% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.60, up 1.73% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $666.51M in 2025 but negative net income margins and ROE. Analyst sentiment is divided with 40% buy ratings, while cash flow trends show heavy investment spending offset by financing activities.
The stock presents a valuation disconnect opportunity with market cap below Forbes' franchise estimates, but faces execution risks from persistent losses and high debt load. Upside depends on Champions League revenue conversion and cost management, while downside risks include sustained profitability challenges in the competitive sports landscape.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
